Unlabeled uses of factor VIIa (recombinant) in pediatric patients
- Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Mason, Jennifer; Pirmohamed, Munir; Nunn, Tony // European Journal of Clinical Pharmacology;Jan2012, Vol. 68 Issue 1, p21
The use of unlicensed and off-label medicines in children is common because trials in children have not usually been performed during the drug development process. Consequently, the information available to paediatricians may not always be as detailed or as robust as that available when...
- Research on patient safety for off-label use of recombinant factor VIIa. Wahi, Monika M.; McKelvey, Russell P.; Gerdik, Cynthia Russell // American Journal of Health-System Pharmacy;4/15/2015, Vol. 72 Issue 8, p600
A letter to the editor is presented in response to the article "Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia" by E. Simpson, S. Stanworth and colleagues published in a previous issue.
- Tamsulosin for Ureteral Stones - Use in a Pediatric Population? Hochwind, Christine; Ashcroft, Kerry // Urologic Nursing;Mar/Apr2012, Vol. 32 Issue 2, p88
Urologists are using tamsulosin (FlomaxÂ®) off-label as an aid for passing ureteral stones. The safety and efficacy of tamsulosin for this condition has been studied extensively in adults; however, studies are lacking in the pediatric population.
- iNO Common Among NICUs Around the U.S. // AARC Times;Jun2012, Vol. 36 Issue 6, p68
The article focuses on the results of the study conducted by Nationwide Children's Hospital researchers regarding the off-label use of inhaled nitric oxide (iNO) in preterm infants in neonatal intensive care units (NICUs) throughout the U.S.
- Recombinant Factor VIIa for Life-Threatening Hemorrhage in Trauma Patients: Review of the Literature. Pape, Hans-Christoph; Erhardtsen, Elisabeth; Meyer, Christian; Leppäniemi, Ari Kalevi // European Journal of Trauma;Oct2006, Vol. 32 Issue 5, p439
The control of hemorrhage and coagulopathy is a vital component of trauma care, and failure to achieve hemostasis can contribute to mortality. Recombinant factor VIIa (rFVIIa) is a well-established therapy for bleeding episodes and surgical prophylaxis in hemophilia patients with inhibitors....
- Drug News. DAVIS, JEANIE // Arthritis Today;Mar/Apr2012, Vol. 26 Issue 2, p56
The article offers drug-related news briefs such as the recommended dose of acetaminophen and the use of mycophenolate mofetil for treatment of lupus nephritis.
- Off-label Panafil Use. Turner, Wm. Barry // Podiatry Management;Mar2014, Vol. 33 Issue 3, p40
A letter to the editor is presented asking for guidance on whether podiatry practices can use papain as an off-label medicine following the removal of Panafil from the market.
- Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications. Yank, Veronica; Tuohy, C. Vaughan; Logan, Aaron C.; Bravata, Dena M.; Staudenmayer, Kristan; Eisenhut, Robin; Sundaram, Vandana; McMahon, Donal; Olkin, Ingram; McDonald, Kathryn M.; Owens, Douglas K.; Stafford, Randall S. // Annals of Internal Medicine;4/19/2011, Vol. 154 Issue 8, p529
Background: Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications. Purpose: To evaluate the benefits and harms of rFVIIa use for 5 off-label, in-hospital indications: intracranial hemorrhage, cardiac surgery, trauma, liver...
- Physicians, advocates call for expanding indications for off-label drugs. Hasson, Matt; Durrie, Daniel S.; Hovanesian, John A.; MacHatton, Doug; Muilenburg, Crystal // Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p54
The article reports that the Alliance of Specialty Medicine urges the expansion of indications for approved drugs used as off label products in response to the federal law which prohibits manufacturers to promote off-label use of the products. It says that the group believes that physicians can...